Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid
Sponsor: Selecta Biosciences, Inc.
A PHASE2 clinical study on Gout Chronic and Hyperuricemia, this trial is completed. The trial is conducted by Selecta Biosciences, Inc. and has accumulated 11 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE2
-
May 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Nov 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Feb 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Selecta Biosciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .